YMAB: Y-mAbs Therapeutics Inc Company Value to Net Income

Y-mAbs Therapeutics Inc - graphic logo of issuer YMAB

Y-mAbs Therapeutics (YMAB) is implementing artificial intelligence for molecule design by leveraging the automated capacities of its partners. The company attracts leading antibody specialists through an RSU system and an ethical approach to work. The market valuation trend at -18.10 confirms the growth potential of DANYELZA and a productive R&D pipeline in the field of precision therapy for pediatric tumors.

Price to Earnings Ratio: Y-mAbs Therapeutics (YMAB) for 07/04/2022 - 09/27/2025

Comprehensive metric breakdowns and analytics for YmAbs (YMAB)

- share price and expert price forecast:
Price Performance Chart ymabs.com|YMAB - Consensus Target
- market capitalization information:
Market Value Y-mAbs Therapeutics, Inc.|YMAB - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Y-mAbs Therapeutics|YMAB - Company Net Assets|Market Capitalization to Book Value Ratio ymabs.com|YMAB - Aggregate Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Y-mAbs Therapeutics|YMAB - Long-Term Debt to Capital|Current Liabilities to Capital Y-mAbs Corp|YMAB - Company Total Debt|Debts to Book Value Y-mAbs Therapeutics, Inc.|YMAB - Company Long-Term Liabilities|Short-Term Indebtedness Y-mAbs Therapeutics|Quick Liquidity Indicator ymabs.com
- company profitability and valuation multiples indicators:
YMAB - Net Profit|Projected Future Earnings Y-mAbs Therapeutics|YMAB - P/E Multiple|Future Price to Earnings Y-mAbs Therapeutics Inc|YMAB - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Y-mAbs Therapeutics, Inc.|YMAB - Operating profit before deduction of amortization|Earnings per share for the trailing year Y-mAbs Therapeutics|YMAB - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months ymabs.com|YMAB - Earnings growth in current year|Expected earnings per share trend next year Y-mAbs Therapeutics
- issuer revenue and sales details:
YMAB - Revenue and Sales Volume|Company Expected Sales Volume ymabs.com|YMAB - Price-to-Revenue Ratio|Forward Price to Sales Y-mAbs Therapeutics, Inc.
General company analysis:YMAB (ymabs.com)
Flagship merchandise of Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics (YMAB) aims for dominance in the pediatric oncology segment through the commercialization of Danyelza. Analyzing the company's P/E chart, an investor sees the ratio of the asset's market value to its net income. This metric determines the theoretical payback period by measuring the cost of every dollar of earned capital. However, ignoring debt growth while scaling the distribution network could create a risk of capital being frozen in an illiquid asset.

Competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple AAPG (Ascentage)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis (PSNL) - Price to Earnings Ratio|Erasca Inc - Company Value to Net Income|DCTH (Delcath) - P/E Multiple|Market Cap to Earnings Aura Corp AURA|Price to Earnings Ratio CADL (Candel Therapeutics)|ARAY - Market Cap to Earnings|SELLAS Life Sciences Group - Price to Earnings Ratio|Market Cap to Net Income Ratio Actuate Therapeutics Inc.|CTOR - Price to Earnings Ratio|TuHURA Biosciences, Inc. (HURA) - Price to Earnings Ratio|TARA: P/E Multiple|fatetherapeutics.com (FATE) - P/E Multiple|WHWK (Aadi Bioscience, Inc.) - P/E Multiple|Price to Earnings Ratio TCRX|Price to Earnings Ratio Champions Oncology (CSBR)|Business Payback Period xbiotech.com|CEL-SCI - Price to Earnings Ratio|Company Value to Net Income OSTX|RADX: Price to Earnings Ratio|Artiva Biotherapeutics, Inc. - Market Price to Net Income Ratio|ANL: P/E Multiple|Veru Corporation - Company Value to Net Income|TPST (Tempest Therapeutics) - P/E Multiple|Market Cap to Earnings Xilio XLO|Price to Earnings Ratio Renovaro Inc. (RENB)|MURA (muraloncology.com) - Company Value to Net Income|P/E Multiple KAPA (Kairos Pharma)|P/E Multiple OnKure Therapeutics, Inc. OKUR|GDTC - Price to Earnings Ratio|Market Cap to Net Income CRIS|APLM: P/E Multiple|Market Cap to Earnings Tharimmune Inc (THAR)|Price to Earnings Ratio ADVB|P/E Multiple Genprex Inc|Price to Earnings Ratio CLDI (Calidi Biotherapeutics)|Market Price to Net Income Ratio SBFM|P/E Multiple XBIO (Xenetic Biosciences, Inc.)|Business Payback Period Salarius Pharmaceuticals Inc (SLRX)|Purple Biotech Corp - P/E Multiple|American Oncology Network (AONC) - Price to Earnings Ratio|BeiGene, Ltd. (BGNE) - Price to Earnings Ratio|CKPT - Business Payback Period|Price to Earnings Ratio ELEV|Market Cap to Earnings iCAD Corp ICAD|Price to Earnings Ratio Ikena Oncology, Inc. (IKNA)|Price to Earnings Ratio Notable Labs Corp NTBL|P/E Multiple VIRX (Viracta Therapeutics, Inc.)|P/E Multiple morphosys.com MOR|NAYA Biosciences Inc. - P/E Multiple|AAPGV: Price to Earnings Ratio